BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23927085)

  • 1. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.
    Le Page AK; Mackie FE; McTaggart SJ; Kennedy SE
    Nephrology (Carlton); 2013 Dec; 18(12):813-9. PubMed ID: 23927085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G; Daniel V; Naujokat C; Döhler B
    Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
    Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
    Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
    Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients.
    Lazda VA
    Transplant Proc; 2006 Dec; 38(10):3404-5. PubMed ID: 17175286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
    Saghafi H; Qorashi M; Heidari A
    Transplant Proc; 2009 Sep; 41(7):2761-3. PubMed ID: 19765428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney-pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience.
    Stratta RJ; Thacker LR; Sundberg AK;
    Transplant Proc; 2005 Mar; 37(2):1271-3. PubMed ID: 15848692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
    Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
    Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation.
    Bischof N; Wehmeier C; Dickenmann M; Hirt-Minkowski P; Amico P; Steiger J; Naegele K; Hirsch HH; Schaub S
    Nephrol Dial Transplant; 2020 Feb; 35(2):346-356. PubMed ID: 31943075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of viral DNA in kidney graft preservation and washing solutions is predictive of posttransplant infections in pediatric recipients.
    Barzon L; Murer L; Pacenti M; Biasolo MA; Vella MD; Ghirardo G; Gamba PG; De Arias AE; Zanon GF; Palù G
    J Infect Dis; 2009 Nov; 200(9):1425-33. PubMed ID: 19803803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Santos AH; Casey MJ; Xuerong W; Womer KL
    Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-associated smooth muscle tumors after kidney transplantation: treatment and outcomes in a single center.
    Tan CS; Loh HL; Foo MW; Choong LH; Wong KS; Kee TY
    Clin Transplant; 2013; 27(4):E462-8. PubMed ID: 23682851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D; Hafferty J; Fulton L; Friend P; Devaney A; Loke J; Welsh KI; Handa A; Klenerman P
    J Clin Virol; 2008 Feb; 41(2):92-5. PubMed ID: 18032098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients.
    Petrisli E; Chiereghin A; Gabrielli L; Zanfi C; Lauro A; Piccirilli G; Baccolini F; Altimari A; Bagni A; Cescon M; Pinna AD; Landini MP; Lazzarotto T
    Transplant Proc; 2010; 42(1):74-8. PubMed ID: 20172284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postlung transplant survival is equivalent regardless of cytomegalovirus match status.
    Russo MJ; Sternberg DI; Hong KN; Sorabella RA; Moskowitz AJ; Gelijns AC; Wilt JR; D'Ovidio F; Kawut SM; Arcasoy SM; Sonett JR
    Ann Thorac Surg; 2007 Oct; 84(4):1129-34; discussion 1134-5. PubMed ID: 17888958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
    Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.